3-Bromopyruvate alleviates the development of monocrotaline-induced rat pulmonary arterial hypertension by decreasing aerobic glycolysis, inducing apoptosis, and suppressing inflammation
Abstract. Background:. Pulmonary arterial hypertension (PH) is a progressive disease with limited therapeutic options, ultimately leading to right heart failure and death. Recent findings indicate the role of the Warburg effect (aerobic glycolysis) in the development of PH. However, the effect of th...
Main Authors: | Jie Liu, Wang Wang, Lei Wang, Xian-Mei Qi, Yu-Hui Sha, Ting Yang, Qiang Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2020-01-01
|
Series: | Chinese Medical Journal |
Online Access: | http://journals.lww.com/10.1097/CM9.0000000000000577 |
Similar Items
-
Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment
by: Tengjiao Fan, et al.
Published: (2019-03-01) -
Inhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis
by: Gandham SK, et al.
Published: (2015-07-01) -
Characteristics of inflammation process in monocrotaline-induced pulmonary arterial hypertension in rats
by: Chao Tang, et al.
Published: (2021-01-01) -
In vitro evaluations of hexokinase-2 inhibition with 3-bromopyruvate encapsulated in targeted liposomal formulations using 3D spheroid models of tumor aerobic glycolysis
Published: () -
Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
by: Yi Tong, et al.
Published: (2018-09-01)